Providing COVID-19 Vaccine Moderna
Helping Recipients Understand What to Expect

The use of COVID-19 Vaccine Moderna is permitted under an interim authorization delivered in accordance with section 5 of the COVID-19 Interim Order (IO)*. Patients should be advised of the nature of the authorization. The interim authorization is associated with Terms and Conditions that need to be met by the Market Authorization Holder to ascertain the continued quality, safety and efficacy of the product. For further information on authorization under this pathway, please refer to Health Canada’s IO Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2 vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 18 years of age and older.

*Available at Health Canada at www.canada.ca/en/health-canada.html

**INDICATION**

COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2 vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 18 years of age and older.

**CONTRAINDICATIONS**

COVID-19 Vaccine Moderna is contraindicated in individuals who are hypersensitive to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container.

Please see the Product Monograph at https://www.modernacovid19global.com/ca/product-monograph.pdf